Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551004 | 1.00 | ALDH1A1 (0.58) | ALDH1A1HTTCASP1CYP1A2MEN1 | |
| SCHEMBL31469070 | 1.00 | ALDH1A1 (0.58) | ALDH1A1HTTCASP1CYP1A2MEN1 | |
| SCHEMBL89126 | 1.00 | ALDH1A1 (0.58) | ALDH1A1HTTCASP1CYP1A2MEN1 | |
| Water SCHEMBL8468949 | 0.98 | ALDH1A1 (0.56) | ALDH1A1HTTCASP1CYP1A2MEN1 | |
| SCHEMBL28145814 | 0.98 | ALDH1A1 (0.56) | ALDH1A1HTTCASP1CYP1A2MEN1 | |
| Methane SCHEMBL27569754 | 0.98 | ALDH1A1 (0.56) | ALDH1A1HTTCASP1CYP1A2MEN1 | |
| SCHEMBL17840964 | 0.92 | ALDH1A1 (0.56) | ALDH1A1HTTCASP1CYP1A2MEN1 | |
| Bicarbonate SCHEMBL8411607 | 0.90 | ALDH1A1 (0.48) | ALDH1A1HTTCASP1CYP1A2MEN1 | |
| Formic Acid SCHEMBL27791720 | 0.88 | ALDH1A1 (0.47) | ALDH1A1HTTCASP1CYP1A2MEN1 | |
| Quinoline SCHEMBL27569771 | 0.88 | ALDH1A1 (0.63) | ALDH1A1HTTCASP1CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735420-A1 | ARYL INDOL-3-YL KETONE AND ARYL INDAZOL-3-YL KETONE INHIBITORS OF KIF18A | Volastra Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4727548-A1 | METHOD OF TREATING CANCER WITH INDOLINE INHIBITORS OF KIF18A | Volastra Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4688750-A1 | SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF AS AMPK ACTIVATORS | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4638433-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| CN-117362293-B | Tricyclic pyrazolopyrimidine arylene ester derivative and application thereof | 中国科学院新疆理化技术研究所 | 2025-06-10 | — | — | CN | disclosed |
| WO-2025090640-A1 | SOLID FORMULATIONS AND POLYMORPHIC FORMS OF INDOLINE INHIBITORS OF KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| EP-4536356-A1 | PYRIDINAMINE DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | Xenon Pharmaceuticals Inc. (CA) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025074120-A1 | NANOPARTICLES FOR EXTENDED RELEASE DRUG DELIVERY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-04-10 | — | — | WO | disclosed |
| EP-3665172-B1 | COMPOUNDS AS POTENTIAL DYE MOLECULES | Lleaf Pty Ltd (AU) | 2025-03-19 | — | — | EP | disclosed |
| CN-115057872-B | Substituted heterocyclo-cyclic compounds, preparation and pharmaceutical use thereof | 劲方医药科技(上海)股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| CN-107810273-B | Method for modifying glycoproteins with a glycosyltransferase that is or is derived from a beta- (1,4) -N-acetylgalactosamine transferase | 西纳福克斯股份有限公司 | 2022-09-27 | — | — | CN | disclosed |
| CN-115087486-A | Substituted bicyclic and tricyclic ureas and amides, analogs thereof, and methods of use thereof | 爱彼特生物制药公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115057872-A | Substituted heterocyclic ring compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2022-09-16 | — | — | CN | disclosed |
| CN-113853373-B | Substituted heterocyclic ring compound, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20220235044-A1 | METHOD FOR SYNTHESIZING 1,7-NAPHTHYRIDINE DERIVATIVES | CHENGDA PHARMACEUTICALS CO LTD (CN) | 2022-07-28 | — | — | US | disclosed |
| EP-3994262-A1 | ENHANCEMENT OF NUCLEIC ACID POLYMERIZATION BY AROMATIC COMPOUNDS | Stratos Genomics Inc. (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-110204544-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2022063308-A1 | CLASS OF 1,7-NAPHTHYRIDINE COMPOUNDS AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2022-03-31 | — | — | WO | disclosed |
| CN-112557354-B | Application of benzonaphthyridine compounds with fluorescence characteristic | 上海交通大学 | 2022-03-01 | — | — | CN | disclosed |
| CN-110256427-B | 2- (morpholin-4-yl) -1, 7-naphthyridine | 拜耳制药股份公司 | 2022-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235044-A1 | METHOD FOR SYNTHESIZING 1,7-NAPHTHYRIDINE DERIVATIVES | ALDH7A1, AKR7A2, APEH | ALDH1A1 9/4885HTT 2602/4885CASP1 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.